Challenges in the care of Ewing’s sarcoma in a Jehovah’s Witness patient

Autor: Vargas-Potes CJ; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. carlospdepotes@gmail.com., Mendoza-Urbano DM; Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia. dimarmend@hotmail.com., Parra-Lara LG; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia; Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia. luisgabrielparralara@hotmail.com., Zambrano ÁR; Servicio de Hemato-Oncología, Departamento de Medicina Interna, Fundación Valle del Lili, Cali, Colombia. angela.zambrano@fvl.org.co.
Jazyk: English; Spanish; Castilian
Zdroj: Biomedica : revista del Instituto Nacional de Salud [Biomedica] 2023 Mar 30; Vol. 43 (1), pp. 44-50. Date of Electronic Publication: 2023 Mar 30.
DOI: 10.7705/biomedica.6720
Abstrakt: Ewing’s sarcoma is a bone and soft tissue neoplasm, whose management is related to hematological toxicity. This aspect represents a medical and ethical challenge in Jehovah’s Witnesses patients, who, due to their religious beliefs, reject the blood component transfusion, with the risk of discontinuing chemotherapy or using suboptimal doses. We present the case of a 34-year-old Colombian woman, Jehovah’s Witness, diagnosed with Ewing’s sarcoma with clinical stage IIB (T1N0M0) in the left maxillary and mandibular regions, treated with chemotherapy, who presented a hemoglobin nadir of up to 4.5 g/dL, and surgical indication as part of the treatment. In these patients, the transfusion decision has ethical implications that require therapeutic alternatives and a multidisciplinary approach.
Databáze: MEDLINE